Switching to biosimilars can result in significant savings

Rising specialty drug costs are challenging the health care system. As a leader in integrated drug management, we promote biosimilar strategies that offer potential savings of $100 billion in five years.

Blue Paper

The Basics

Biosimilars are safe, effective alternatives to brand products

A biosimilar is a biologic that is highly similar to and has no clinically meaningful differences from a similar, FDA-approved biologic. Biosimilars are newer to the market but are typically less expensive than the reference brand product.

Ground yourself in biosimilar basics

Explores the differences in the regulatory pathways between generics and biosimilars.

Top 10 biosimilar acronyms

It’s okay not to know (or remember) all of the answers all of the time.

Getting biosimilars to market

Explains what works and what doesn’t when getting biosimilars to market.

Case study

Converting a drug class to biosimilars

In Prime’s case study, three Blue plans added biosimilars to their formularies and preferred them, which collectively delivered a savings of $4 million in 2019. If all of Prime’s Blue Plan clients did the same and adoption rates followed, we project savings of $41-$55 million per year.


A PCMA podcast: Understanding the value of biosimilars

Host JC Scott leads a discussion on strategies to increase the use of biosimilars and drive lower specialty drug costs. He’s joined by Dr. Joseph Leach, Prime’s Senior Vice President and Chief Medical Officer and Jarrod Henshaw, Prime’s Senior Vice President and Innovation & Supply Chain Officer.



Leveraging the collective strength of Prime’s client membership to help control medical costs by including biosimilars, medical rebates and low net cost savings.


Press releases

November 3, 2021

Prime Therapeutics backs first interchangeable insulin biosimilar Semglee®

EAGAN, Minn. – Prime Therapeutics LLC (Prime), a leading pharmacy benefit manager (PBM)…


October 15, 2021

Prime leaders discuss the emerging opportunity for biosimilars

MILI and Prime Therapeutics leadership led a virtual panel discussion on Oct. 13,…


June 18, 2021

Three Minutes with April Kunze, Senior Director of Clinical Program Development

April Kunze manages Prime’s formulary development process. She oversees the various internal committees…